AgingResearch.NewsJoin free

4D Molecular Therapeutics

CompanyUnited States

4D Molecular Therapeutics develops one asset, in phase 3 (4D-150 in diabetic macular edema). Mostly gene therapy acting on VEGFA, PGF and VEGFC; based in the United States.

1
Asset
Furthest stage
Phase 3
1
Trial
2
Signals

Pipeline

1

  • 4D-150

    Intravitreal gene therapy expresses aflibercept and a VEGFC-targeting microRNA to suppress vascular leakage and abnormal blood vessel growth.

    Phase 3, Gene therapy, VEGFA, PGF, diabetic macular edema

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Signals2
  • Similar companies6

Intelligence